Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
SAN$12.14+0.07(+0.58%)Opportunity to Earn More on Savings Reemerging as Middle-Income Households Seek to Offset Price Pressures10:00:15 AM ETGILD$176.34+1.86(+1.07%)Positive Phase 3 IDEAL Study Results Further Support Livdelzi®’s (Seladelpar) Impact on Achieving ALP Normalization Goals in Second-Line Treatment Across a Broad Population of People Living with Primary Biliary Cholangitis (PBC)10:00:05 AM ETCL$100.19+1.43(+1.45%)Oral Irrigator Market Size, Share, Trends, and Growth Forecast, 2026-2033 | Market to Reach $2.49 Billion as AI-Assisted Devices and Preventive Oral Care Drive 7.8% CAGR9:57:39 AM ETCRWV$43.96-4.44(-9.17%)UPDATE 2-AI, data-center stocks slip as Democratic sweep clouds expansion plans9:54:48 AM ETKLAC$139.29-10.36(-6.92%)KLA: Unfairly Caught Up In The Tech Carnage9:53:49 AM ETAAPL$349.12-0.44(-0.13%)Apple seeks about $7 billion from bond sale, Bloomberg News reports9:52:21 AM ETTSLA$346.97-38.21(-9.92%)Tesla vs. BYD: Which EV Giant Is Better Charged Right Now?9:50:49 AM ETAAPL$349.12-0.44(-0.13%)Green Electronics Manufacturing - Global Strategic Business Report 2026: Capitalize on a 24.6% CAGR and $90.8 Billion by 2032, Led by Apple, BYD, Foxconn, Samsung, and Siemens9:47:48 AM ETCOP$140.35+3.47(+2.54%)ConocoPhillips Just Raised Its Dividend 11%. Is the Stock a Buy?9:47:46 AM ETBRK-A$876,326.00+7,711.00(+0.89%)Berkshire Has Gained 16% in About 5 Weeks9:47:19 AM ETDD$152.42+1.64(+1.09%)Global Roofing Market: Size, Share, Trends and Forecast 2026-2032 | Market to Reach $377.73 Billion as Climate Resilience, Energy Upgrades, and AI-Enabled Inspections Drive 5% CAGR9:46:38 AM ETBRK-A$876,326.00+7,711.00(+0.89%)Prediction: Berkshire Hathaway Stock Tops $700 a Share Before the End of 20309:45:00 AM ETV$437.73+1.14(+0.26%)Visa Releases First-of-Its-Kind Industry Benchmark for AI Shopping; Almost Half of Test Runs Fail9:43:00 AM ETCAT$569.10-22.00(-3.72%)Demolition Tools Market - Global Forecast 2026-2032 | Market to Reach USD 4.81 Billion as Battery Power, AI, and Circular Construction Drive Growth9:36:39 AM ETARM$169.37-22.91(-11.91%)Arm Just Shipped 10 Billion Chips in a Single Quarter for the First Time9:31:16 AM ETAVGO$307.22-18.48(-5.67%)Power Semiconductor Module Market - Global Forecast 2026-2032 | Electrification, AI Data Centers, and Wide-Bandgap Adoption Drive 7.68% CAGR Toward USD 76.66 Billion9:30:42 AM ETMSFT$543.36-12.65(-2.28%)Tech Volatility Grips Stock Market as Blue Chips Lead; OpenAI to Pay for Data Center Power9:30:13 AM ETPLTR$157.63-14.11(-8.22%)Is Palantir Stock a Buy on the Dip as Revenue Continues to Surge?9:30:00 AM ETTMO$701.20-4.83(-0.68%)AI in Genomics Market Size, Share, Growth, and Competitive Analysis - Global Forecast 2026-2035 | 32.40% CAGR to USD 14.55 Billion as Precision Medicine and Drug Discovery Scale9:27:39 AM ETC$123.67-1.10(-0.88%)UPDATE 7-Oil rises as investors weigh uncertainties around Iran war9:25:37 AM ETAMZN$261.61-4.58(-1.72%)Global Delivery Drones Market by Payload, Range, MTOW, Platform, Application, and Region - Forecast to 2031 | Healthcare and Hybrid Drones Fuel 21.6% CAGR to $7.65 Billion9:23:39 AM ETRDW$6.66-1.05(-13.62%)BUZZ-US STOCKS ON THE MOVE-ConocoPhillips, Sezzle, Cardinal Health9:20:53 AM ETAMD$425.08-63.61(-13.02%)Heterogeneous Computing Market Size and Share - Industry Trends and Growth Forecasts (2026-2031) | Generative AI and Cloud Adoption Fuel 21.87% CAGR9:20:42 AM ETCOHR$175.29-19.93(-10.21%)Coherent Now Sees Growth Above 60% and Its First $4 Billion Quarter by Fiscal 20289:19:53 AM ET

BIVI · NASDAQ

BioVie Inc.

$1.15 -0.19 (-14.18%)

Company overview

BioVie Inc. is a clinical-stage biotechnology company engaged in the discovery, development, and commercialization of drug therapies in the United States. Its pipeline includes BIV201, which completed a Phase IIa clinical trial for treating ascites due to chronic liver cirrhosis, and NE3107, which is in a Phase III clinical trial for patients with mild to moderate Alzheimer's disease and a Phase I clinical trial for Parkinson's disease. The company is also developing NE3107 in the pre-clinical stage for multiple myeloma and prostate cancer. Formerly known as NanoAntibiotics, Inc., the company changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Carson City, Nevada.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$10M
Employees
14
Headquarters
Carson City, NV
Website
bioviepharma.com
CEO
Cuong Viet Do
Listed
September 18, 2020
P/E
-0.78
Dividend yield
0.00%

Company financials

Revenue
$0.00
Gross profit
-$229,376
Operating income
-$20.6M
EBITDA
-$20M
Net income
-$19.9M
EPS
-$1.47
Total assets
$17.5M
Total debt
$295,717
Earnings yield
-127.83%

Price chart

0.701.502.313.113.91
BIVI 1D NASDAQ O1.64H1.65L1.23C1.34-0.40 (-22.83%)Vol882.65K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
View
Ticker Type Headline Source Published
BIVIBioVie Inc. Press release BioVie Announces Pricing of $4.74 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules GlobeNewswire
BIVIBioVie Inc. Press release BioVie Selected for Late-Breaking Oral Presentation of Bezisterim Long COVID Data at the 4th Long COVID International Conference 2026 GlobeNewswire
BIVIBioVie Inc. Press release From Global Private Credit to Programmable Securities: New to The Street Show #778 Premieres Tonight on Bloomberg Television ACCESS Newswire
BIVIBioVie Inc. Press release BioVie Invited to Present Data on Bezisterim in Long COVID at the NIH’s RECOVER-TLC Third Annual Workshop GlobeNewswire
BIVIBioVie Inc. Press release From Private Credit to Fusion Power: New to The Street Show #777 Premieres Tonight on Bloomberg Television ACCESS Newswire
BIVIBioVie Inc. Press release BioVie Presents Data on Bezisterim in Parkinson’s Disease at the 2026 American Neurological Association Annual Meeting GlobeNewswire
BIVIBioVie Inc. Stock news BioVie says bezisterim eased fatigue and cognitive symptoms in Long COVID subgroups Proactive Investors
BIVIBioVie Inc. Press release BioVie Presents Data on Bezisterim in Long COVID at the 2026 American Neurological Association Annual Meeting GlobeNewswire
BIVIBioVie Inc. Press release Powering the AI Economy: New to The Street Show #776 Premieres Tonight on Bloomberg Television ACCESS Newswire
BIVIBioVie Inc. Stock news BioVie to present Long COVID and Parkinson's trial results at American Neurological Association meeting Proactive Investors
BIVIBioVie Inc. Press release BioVie to Present New Bezisterim Findings in Parkinson’s Disease and Long COVID at the 2026 American Neurological Association Annual Meeting GlobeNewswire
BIVIBioVie Inc. Press release New to The Street Show 775 Premieres Tonight on Bloomberg Television Across the United States, Latin America, MENA and Southeast Asia, Featuring American Fusion, HPB, T-REX Acquisition Corp. and SyncMeOn ACCESS Newswire
BIVIBioVie Inc. Press release New to The Street Show 773 Premieres Tonight on Bloomberg Television, Featuring Glint, Sagtec Global, BioVie and SafeSpace Global ACCESS Newswire
BIVIBioVie Inc. Stock news BioVie Inc. (BIVI) Discussion of Phase 2 data on bezisterim in Long COVID and Parkinson's with focus on inflammation targets Transcript Seeking Alpha
BIVIBioVie Inc. Press release New to The Street Broadcasts Tonight at 6:30 PM ET Across the United States, Latin America and MENA, Featuring BioVie, Acurx Pharmaceuticals, Lantern Pharma and SafeSpace Global ACCESS Newswire
BIVIBioVie Inc. Press release Alliance Entertainment and BioVie Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV ACCESS Newswire
BIVIBioVie Inc. Press release Join BioVie's Exclusive Live Investor Webinar: Inside the ADDRESS-LC Phase 2 Results ACCESS Newswire
BIVIBioVie Inc. Stock news BioVie Inc. (BIVI) Discusses Topline Phase 2 ADDRESS-LC Trial Data and the Potential of Bezisterim in Long Covid Transcript Seeking Alpha
BIVIBioVie Inc. Stock news What's Going On With BioVie Stock on Tuesday? Benzinga
BIVIBioVie Inc. Press release BioVie Announces Topline Results from Phase 2 ADDRESS‑LC Trial Evaluating Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID GlobeNewswire
See more
FAQ

Questions about BioVie Inc.

What does BioVie Inc. do?
BioVie Inc. is a clinical-stage biotechnology company engaged in the discovery, development, and commercialization of drug therapies in the United States. Its pipeline includes BIV201, which completed a Phase IIa clinical trial for treating ascites due to chronic liver cirrhosis, and NE3107, which is in a Phase III clinical trial for patients with mild to moderate Alzheimer's disease and a Phase I clinical trial for Parkinson's disease. The company is also developing NE3107 in the pre-clinical stage for multiple myeloma and prostate cancer. Formerly known as NanoAntibiotics, Inc., the company changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Carson City, Nevada.
What is BIVI's market cap?
BioVie Inc. (BIVI) is a listed stock with a live quote. The latest market cap on this page is $10M.
Where is BioVie Inc. headquartered?
BioVie Inc. is headquartered in Carson City, NV.
How do I get BIVI news from the API?
Call GET /v1/news?tickers=BIVI. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does BIVI news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for BIVI, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the BIVI price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 250 REST requests a day, 1 WebSocket connection, 5 requests per second, and 2,500 WebSocket messages a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs